{"organizations": [], "uuid": "76c3e652a575605eea1037c629c087290980faa9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/8", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/19/globe-newswire-cellectar-biosciences-to-host-2017-financial-results-and-business-update-conference-call-on-march-22-2018.html", "country": "US", "domain_rank": 767, "title": "Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T15:00:00.000+02:00", "replies_count": 0, "uuid": "76c3e652a575605eea1037c629c087290980faa9"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/19/globe-newswire-cellectar-biosciences-to-host-2017-financial-results-and-business-update-conference-call-on-march-22-2018.html", "ord_in_thread": 0, "title": "Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "madison", "sentiment": "none"}, {"name": "wis.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "cellectar biosciences", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that management will host a teleconference and live webcast to report financial results for the 12 months ended December 31, 2017 and to provide a business update on Thursday, March 22, 2018 at 8:30 AM ET.\nEvent Details\nInterested investors may participate in the conference call by dialing 844-751-1093 (US domestic) or 574-990-2954 (international) and providing conference ID 6674595, or participate via webcast at https://edge.media-server.com/m6/p/ehq7d7vj . The live and archived webcast can be accessed via the company's website at investor.cellectarbiosciences.com/events-and-presentations .\nFor those unable to participate in the live conference call or webcast, a replay will be available beginning March 22, 2018 two hours after the close of the conference call. To access the replay, dial 855-859-2056 or 404-537-3406. The replay passcode is 6674595.\nAbout Cellectar Biosciences, Inc.\nCellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company plans to develop proprietary drugs independently and through research and development (R&D) collaborations. The core drug development strategy is to leverage our Phospholipid Drug Conjugate™ (PDC) platform to develop therapeutics that specifically target treatment to cancer cells. Through R&D collaborations, the company’s strategy is to generate near-term capital, supplement internal resources, gain access to novel molecules or payloads, accelerate product candidate development and broaden our proprietary and partnered product pipelines.\nThe company's lead PDC therapeutic, CLR 131, is in a Phase 1 clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of B-cell malignancies. In 2018 the company plans to initiate a Phase 1 study with CLR 131 in pediatric solid tumors and lymphoma, and a second Phase 1 study in combination with external beam radiation for head and neck cancer. The company’s product pipeline also includes two preclinical PDC chemotherapeutic programs (CLR 1700 and 1900) and partnered assets include PDCs from multiple R&D collaborations.\nFor more information please visit www.cellectar.com .\nForward-Looking Statement Disclaimer\nThis news release contains forward-looking statements. You can identify these statements by our use of words such as \"may,\" \"expect,\" \"believe,\" \"anticipate,\" \"intend,\" \"could,\" \"estimate,\" \"continue,\" \"plans,\" or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.\nCONTACT:\nLHA Investor Relations\nAnne Marie Fields\n212-838-3777\nafields@lhai.com\nSource:Cellectar Biosciences, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=d5NnV9rXTo-xSB4HO_-uhybVN9FbbFkdqIDnboIaNMtyF6G0Hc6HRlVQdPz0lgN3CFThN2YTd5ptrMhDndCooDJdXjn--nQB-hMK4_yRrigf4cYjiePcHowXryl-MTBjib31Jr5PaPDcD-duTCofjg1Jpvk1YBiR28mxRkeYf5qsR5TqMKhTCR6Ieyn-0SStl7LMGUgQB8DHyxPVBBz1I_QSY_TX78ZDOEUgBFJRsaE=", "https://www.globenewswire.com/Tracker?data=Zl7TntIIrwPyc5V25nRvZ0Ir2R4B-t6O9SDKwFYHwmgusDg8Epl6VxR0Y5DQqAj33XXt7eUUwmO19EzhnVidbhhVq9OaXMrmgqbdGDg88Gpzuv0b3PsEUTUlThcBre_MAvibPCzLi3ZgGv-qwaQ9QmoQoCJuFDVKPbim_MLbl8fev1_aCEsfp0u-bsXr4ugiiQeESY4ns1yEAH2vpRZqsw==", "https://edge.media-server.com/m6/p/ehq7d7vj", "https://www.globenewswire.com/NewsRoom/AttachmentNg/980abc5d-826f-4ac3-ad81-f07d69b34af6", "https://www.globenewswire.com/Tracker?data=LDYTRWu_EMfXNx9RqsNDr_-RRqbVShMKE2G-sEvRBf_HMgzqW2xlLKL8XU4UrlP451kGdepwaQG6m5BR-RaW0Z4EXT7K7DGtHMm71jqpIi9BSZOfb6OYB1Hn2NBDKYXhGTAjrlIFWpRdleN5YC2-KQ=="], "published": "2018-03-19T15:00:00.000+02:00", "crawled": "2018-03-19T16:47:53.001+02:00", "highlightTitle": ""}